ProfileGDS5678 / 1418479_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 92% 92% 91% 94% 92% 94% 93% 93% 92% 91% 92% 92% 92% 92% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.4810592
GSM967853U87-EV human glioblastoma xenograft - Control 27.689192
GSM967854U87-EV human glioblastoma xenograft - Control 37.554591
GSM967855U87-EV human glioblastoma xenograft - Control 48.3540594
GSM967856U87-EV human glioblastoma xenograft - Control 57.7308992
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.7730794
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.5696493
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.7903593
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.629992
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.403491
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.587192
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.6782292
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.6190592
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.5659992